Pipeline
ERX Pharmaceuticals is focused on the discovery and development of innovative drugs for the treatment of obesity and related diseases, with several drug candidates in the pipeline.
Clinical Stage Candidates
ERX-1000, a leptin sensitizer currently in Phase 1, is ERX’s lead drug candidate.
For more information on ERX-1000 click here.
ERX-1000 (Obesity)
Preclinical and Discovery Stage Candidates
Research efforts around next generation candidates include advancing several active, novel analogs of ERX-1000 through preclinical development.
Next Generation Candidates (Obesity)
| 2019 | 2020 | 2021 | |
|---|---|---|---|
| Candidate Selection | |||
| IND Enabling Studies | |||
| Phase 1 |
ERX-2000 is another class of leptin-sensitizing compound that is distinct from ERX-1000. ERX-2000 has shown anti-diabetic activity and has also shown weight-lowering effects in preclinical animal models.
ERX-2000 (Diabetes)
| 2019 | 2020 | 2021 | |
|---|---|---|---|
| Discovery / Preclinical | |||
| IND Enabling Studies |
For more information on future development candidates click here.